Cover

Front Matter

Contents

Preface

Eosinophilic Inflammation in Peritoneal Fibrosis Patients Undergoing Peritoneal Dialysis

Abstract

Expectations and Challenges of PD Therapy

Pathogenesis of EPS and the Innate Immune System

Eosinophils and the Innate Immune System

Towards Restriction of EPS

Disclosure Statement

Funding Sources

References

Chapter 1: New Opinions on Dialysis Therapy

Current Perspectives on Sudden Cardiac Death in Hemodialysis Patients

Abstract

SCD in Japanese Dialysis Patients

The Definition of Sudden Death

HD Patient-Specific Underlying Cardiac Abnormalities Related to SCD

Is Ventricular Fatal Arrhythmia the Main Cause of SCD in HD Patients?

HD Cycle and Onset of SCD

Long QT Interval due to Dialysis Solution

Conclusions

Disclosure Statement

Funding Sources

References

Strategy for Prevention of Left Ventricular Remodeling in Predialysis and Dialysis Patients

Abstract

Methods

Results

Discussion

Conclusions

Acknowledgments

Disclosure Statement

Funding Sources

References

Asymptomatic Cerebrovascular Disease in Dialysis Patients

Abstract

Stroke in Dialysis Patients

Asymptomatic Cerebral Small Vessel Disease in Dialysis Patients

Conclusion

References

Brain Atrophy and Cognitive Impairment in Chronic Kidney Disease

Abstract

Brain Atrophy in Dialysis Patients

Relationship between Brain Atrophy and Cognitive Function in CKD Patients

Factors Associated with Cognitive Impairment

Relationship between CKD and Dementia

Mechanism of Cognitive Impairment in CKD

Acknowledgements

Disclosure Statement

Funding Sources

References

Conclusions

Targets and Therapeutics for Glycemic Control in Diabetes Patients on Hemodialysis

Abstract

Glycemic Control Index and Target Value

Frequency of Monitoring Glycemic Control Indicators

Hemodialysis-Induced Hyperglycemia

Treatment

Conclusion

Conflicts of Interest

Funding Sources

References

Hypoglycemia

Intravenous Maxacalcitol Therapy Correlates with Serum Fibroblast Growth Factor 23 Levels in Hemodialysis Patients Independent of Serum Phosphate or Calcium Levels

Abstract

Patients and Methods

Results

Discussion

Statement of Ethics

Disclosure Statement

References

Conclusions

Importance of Physiological Erythropoiesis in the Treatment of Chronic Kidney Disease-Associated Anemia

Abstract

Hyporesponsiveness to ESAs, Iron Metabolism, and Prognosis in MHD Patients

Dysutilization of Iron for Erythropoiesis and Prognosis in MHD Patients

Treatment of CKD-Associated Anemia Based on Physiological Erythropoiesis

Conclusion

References

Magnesium in Hemodialysis Patients: A New Understanding of the Old Problem

Abstract

Magnesium Status in Hemodialysis Patients

Magnesium and Vascular Calcification

Magnesium and Cardiovascular Outcomes in Hemodialysis Patients

Magnesium and the Risk of Fracture

Conclusion

Disclosure Statement

Funding Sources

References

Does Combined Therapy with Peritoneal Dialysis and Hemodialysis Improve Prognosis?

Abstract

Clinical Experience of Combined Therapy with PD and HD

Effect of Combined Therapy on Morbidity andMortality

Limitations and Future Outlook

Conclusion

Acknowledgments

Disclosure Statement

Funding Sources

References

Pathogenesis and Management of Vascular Calcification in Patients with End-Stage Renal Disease

Abstract

Intimal and Medial Arterial Calcification

Mineral Metabolism and Vascular Calcification

Role of Fibroblast Growth Factor-23 and Sclerostin in Vascular Calcification

Assessment of Vascular Calcification

Treatment of Vascular Calcification

Conclusion

References

Chapter 2: Hemodialysis (Complications, Nursing Care, Home Care)

Total Renal Care Approach for Patients with End-Stage Renal Disease

Abstract

Case Report

Perspective on Chronic Disease Patient Education

The Total Renal Care Approach and Stage of Acceptance toward ESRD

Intervention That Enables Self-Management

Conclusion

Acknowledgments

Disclosure Statement

References

Ferritin: Diversity and Management of Ferritin Measurement Methods

Abstract

Basics of Ferritin

Methods for Measuring Serum Ferritin

Methods to Assess Systematic Bias

Evaluation and Effects of Systematic Bias among Serum Ferritin Measurement Methods

Dealing with Systematic Bias

Conclusion

Disclosure Statement

Funding Sources

References

Current Status and Treatment Strategies of Hemodialysis-Associated Pruritus

Abstract

Epidemiology and Clinical Characteristics

Pathogenesis

Treatment Strategies Using the Therapeutic Algorithm

Evaluation of Usefulness of Therapeutic Algorithm

Conclusion

Funding Sources

References

Acknowledgements

Disclosure Statement

Effects of Levocarnitine on Cardiac Function and Renal Anemia in Hemodialysis Patients

Abstract

Effects on Nephrogenic Anemia

Improvements in Cardiac Functions

Conclusion

Disclosure Statement

Funding Sources

References

Management of Physical Frailty in Patients Requiring Hemodialysis Therapy

Abstract

Evaluation of Frailty in the Hemodialysis Population

Physical Activity and Physical Performance

Exercise Training in CKD Patients

Management of Physical Frailty in Hemodialysis Patients

Conclusions

Disclosure Statement

Funding Sources

References

Advances and Developments in Vascular Access in Japan

Abstract

New Materials and Artificial Products

Quality of VA Management and Its Relationship with Types of Complications

Aging

Promising New Devices

Disclosure Statement

Funding Sources

References

Intermittent Infusion Hemodiafiltration: The Principle and Its Clinical Application

Abstract

Principle of I-HDF

Clinical Effects of I-HDF

Future Outlook

Conclusions

Acknowledgement

References

Treatment of Hepatitis C Virus Infection in Dialysis Patients

Abstract

DAAs – A Paradigm Shift in the Treatment of Hepatitis C

DAA Therapies in Hemodialysis Patients

DAA Treatment Options for Chronic Hepatitis C in Hemodialysis Patients

Conclusion

References

Chapter 3: Peritoneal Dialysis, Home Dialysis

Current Status of Peritoneal Dialysis in Japan

Abstract

Survival Rate

Residual Renal Function

Peritonitis, Exit Site Infection

Encapsulating Peritoneal Sclerosis

Combination Therapy

Conclusion

Disclosure Statement

References

Current State of Peritoneal Dialysis in Children

Abstract

Methods

Results

Discussion

Conclusion

Acknowledgements

Disclosure Statement

Funding Sources

References

Effect of Combined Peritoneal Dialysis and Hemodialysis on Health-Related Quality of Life

Abstract

Methods

Results

Discussion

Conclusions

Disclosure Statement

Funding Sources

References

Peritoneal Dialysis in Elderly Patients

Abstract

Methods

Results

Discussion

Conclusions

Disclosure Statement

Funding Sources

References

Blood Pressure Control in Peritoneal Dialysis Patients

Abstract

Definition and Prevalence of HT

CV Risk and HT in PD Patients

Monitoring BP and Weekly BP Variability

Treatment of BP

Disclosure Statement

References

Conclusion

The Role of Non-Tuberculous Mycobacteria in Peritoneal Dialysis-Related Infections: A Literature Review

Abstract

PD-Related NTM Peritonitis

PD-Related NTM-ESI and Tunnel Infections

Discussion

Conclusion

Acknowledgements

References

Translational Research of Peritoneal Dialysis Solution with Dissolved Molecular Hydrogen

Abstract

Methods

Results

Discussion

Conclusion

Disclosure Statement

Funding Sources

Author Contributions

References

A Perspective on the Current Status of Home Hemodialysis

Abstract

Historical Change in Hemodialysis Prescription of Hours and Frequency

Optimal Dialysis Prescription: “HD Products”

Randomized Controlled Trials of Intensive HD

The Challenges of Home HD

Home HD in Japan

Technical Advances in Home HD

References

Home Hemodialysis: Benefits, Risks, and Barriers

Abstract

Clinical Benefits of HHD

Risks of HHD

Barriers to Increased Introduction of HHD

Conclusion

Disclosure Statement

Funding Sources

References

Intensive Hemodialysis: Effects of Treatment Time and Frequency on Time-Averaged Concentrations of Solutes

Abstract

Methods

Results and Discussion

Conclusions

References

Chapter 4: AKI, Apheresis, and Cross-Sections

Apheresis for Kidney Disease

Abstract

Target Diseases

Rapid Progressive Nephritic Syndrome

Nephrotic Syndrome

Some Important Points in Apheresis Therapy for Kidney Disease

Conclusion

References

Our Approaches to Selective Plasma Exchange

Abstract

Conventional PE Treatments

Characteristics of the Selective Separation Membrane We Used

sievingcoefficient. The testing conditions are as follows:blood flow rate = 100 ± 2 ml/min; filtrationrate = 30 ± 1 ml/min; blood from cows:TP = 6.0 ± 0.5 g/dL, Hct = 32 ± 2%; total timemeasured: 60 min.The Structure of the Circuit

Cases of PE and Plasma Adsorption

Conclusion

References

Changes in Treatment with Granulocyte and Monocyte Adsorptive Apheresis from the Past to Future in Patients with Inflammatory Bowel Disease

Abstract

Introduction

Clinical Trials of GMA in Patients with IBDs to Date

Future Issues of GMA in IBD

Conclusion

Disclosure Statement

Funding Sources

References

Current Practices in Acute Blood Purification Therapy in Japan and Topics for Further Study

Abstract

Modality Selection in Japan and Outcomes by Modality

Unique Aspects of Certain Continuous Blood Purification Therapy Practices in Japan

Conclusion

Disclosure Statement

Funding Sources

References

Evidence and Perspectives on the Use of Polymyxin B-Immobilized Fiber Column Hemoperfusion among Critically Ill Patients

Abstract

Evidence for PMX Hemoperfusion

Mechanisms of PMX Hemoperfusion

Novel Findings for PMX

Conclusions

Disclosure Statement

Funding Sources

References

Current Trend of Pediatric Renal Replacement Therapy in Japan

Abstract

The Japanese Society for Pediatric Nephrology (JSPN) ESRD Survey 2012

Epidemiology and Demographics of Pediatric ESRD in Japan

Current Trend of Pediatric RRT in Japan

Conclusion

Acknowledgments

Disclosure Statement

References

Dysnatremia in Renal Failure

Abstract

Morphological Changes in Nephron Segment Associated with CRF

Function of Salt and Water Reabsorption in Hypertrophied Nephron

Dysnatremia in Patients with Renal Failure

References

Methods We Currently Use for Home Hemodialysis Management

Abstract

Deciding on the Best Treatment Plan for Each Patient

Introducing Patients to HHD

Management following HHD Training

Conclusion

References

Protein Energy Wasting and Sarcopenia in Dialysis Patients

Abstract

Frailty in Dialysis Patients

Sarcopenia in Dialysis Patients

PEW in Dialysis Patients

References

Author Index

Subject Index

Cover